Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial

BACKGROUND: This open-label, multicentre, phase II/III trial assessed the noninferiority of trifluridine/tipiracil (FTD/TPI) plus bevacizumab vs. fluoropyrimidine and irinotecan plus bevacizumab (control) as second-line treatment for metastatic colorectal cancer (mCRC). METHODS: Patients were random...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuboki, Yasutoshi, Terazawa, Tetsuji, Masuishi, Toshiki, Nakamura, Masato, Watanabe, Jun, Ojima, Hitoshi, Makiyama, Akitaka, Kotaka, Masahito, Hara, Hiroki, Kagawa, Yoshinori, Sugimoto, Naotoshi, Kawakami, Hisato, Takashima, Atsuo, Kajiwara, Takeshi, Oki, Eiji, Sunakawa, Yu, Ishihara, Soichiro, Taniguchi, Hiroya, Nakajima, Takako Eguchi, Morita, Satoshi, Shirao, Kuniaki, Takenaka, Naruhito, Ozawa, Daisuke, Yoshino, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147634/
https://www.ncbi.nlm.nih.gov/pubmed/36871043
http://dx.doi.org/10.1038/s41416-023-02212-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147634/
https://www.ncbi.nlm.nih.gov/pubmed/36871043
http://dx.doi.org/10.1038/s41416-023-02212-2

Ejemplares similares